1)日本食道学会編.食道癌診療ガイドライン2017年版,第4版.金原出版,pp 16-23, 2017
2)Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. Gastroenterology 157:382-390, 2019
3)Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma:Japan Clinical Oncology Group Study(JCOG9708). Jpn J Clin Oncol 39:638-643, 2009
4)Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology 161:1878-1886, 2021
5)Hatta W, Koike T, Takahashi S, et al. Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa:a multicenter retrospective study. J Gastroenterol 56:620-632, 2021
6)Tanaka T, Ueno M, Iizuka T, et al. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma. Dis Esophagus 32:doz023, 2019
7)Koterazawa Y, Nakamura T, Oshikiri T, et al. A comparison of the clinical outcomes of esophagectomy and chemoradiotherapy after noncurative endoscopic submucosal dissection for esophageal squamous cell carcinoma. Surg Today 48:783-789, 2018
8)Naito S, Yoshio T, Ishiyama A, et al. Long-term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a-muscularis mucosae and T1b-submucosa by endoscopic resection followed by appropriate additional treatment. Dig Endosc 34:793-804, 2022